See also: Generic Risperdal
Risperdal Consta is a brand name of risperidone, approved by the FDA in the following formulation(s):
RISPERDAL CONSTA (risperidone - injectable; intramuscular)
Manufacturer: JANSSEN PHARMS
Approval date: October 29, 2003
Strength(s): 25MG/VIAL [RLD], 37.5MG/VIAL, 50MG/VIAL
Manufacturer: JANSSEN PHARMS
Approval date: April 12, 2007
Strength(s): 12.5MG/VIAL
Has a generic version of Risperdal Consta been approved?
No. There is currently no therapeutically equivalent version of Risperdal Consta available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Risperdal Consta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Patent 5,688,801
Issued: November 18, 1997
Inventor(s): Mesens; Jean & Rickey; Michael E. & Atkins; Thomas J.
Assignee(s): Janssen Pharmaceutica
Alkermes Controlled Therapeutics Inc. II
A pharmaceutical composition comprising a biodegradable and biocompatible composition comprising a 1,2 benzazole within a polymeric matrix. The 1,2 benzazole composition, pharmaceutically acceptable acid addition salts thereof, are potent antagonists of a series of neurotransmitters, particularly serotonin and dopamine. A method of inhibiting both serotonergic overactivity and dopaminergic overstimulation in animals is provided by administration of a biodegradable and biocompatible microparticle composition comprising a 1,2 benzazole or a pharmaceutically acceptable acid addition salt thereof. A method of treating warm blooded animals suffering from psychotic disorders, and a method of preparing the biodegradable and biocompatible composition are also described.Patent expiration dates:
- November 18, 2014✓
- November 18, 2014✓
- May 18, 2015✓
- November 18, 2014
Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
Patent 5,792,477
Issued: August 11, 1998
Inventor(s): Rickey; Michael E. & Ramstack; J. Michael & Lewis; Danny H. & Mesens; Jean
Assignee(s): Alkermes Controlled Therapeutics, Inc. II
Janssen Pharmaceutica
A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymeric encapsulating binder, and an active agent having limited water solubility dissolved or dispersed in a solvent. An aqueous second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The two phases are separated. The discontinuous first phase is washed with water, or an aqueous solution of water and a solvent for residual solvent in the first phase, to reduce the level of residual solvent in the microparticles to less than about 2% by weight of the microparticles. Also disclosed are a microencapsulated drug prepared by the method for preparing biodegradable, biocompatible microparticles, and a pharmaceutical composition that includes biodegradable and biocompatible microparticles in a pharmaceutically acceptable carrier.Patent expiration dates:
- May 2, 2017✓
- November 2, 2017✓
- May 2, 2017
Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
Patent 5,916,598
Issued: June 29, 1999
Inventor(s): Rickey; Michael E. & Ramstack; J. Michael & Lewis; Danny H.
Assignee(s): Alkermes Controlled Therapeutics Inc. II
A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymer, an active agent, and a solvent. An immiscible second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The two phases are immersed in a quench liquid that includes a quench medium and a quantity of the solvent. The quantity of the solvent is selected to control a rate of extraction of the solvent from the first phase. The first phase is isolated in the form of microparticles. Also disclosed is a microencapsulated active agent prepared by the method for preparing biodegradable, biocompatible microparticles.Patent expiration dates:
- May 2, 2017✓
- November 2, 2017✓
- May 2, 2017
Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Patent 5,965,168
Issued: October 12, 1999
Inventor(s): Mesens; Jean & Rickey; Michael E. & Atkins; Thomas J.
Assignee(s): Alkermes Controlled Therapeutics, Inc. II
Janssen Pharmaceutica
The invention relates to a pharmaceutical composition comprising a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof, within a polymeric matrix.Patent expiration dates:
- November 19, 2013✓
- May 19, 2014✓
- November 19, 2013
Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
Patent 6,110,503
Issued: August 29, 2000
Inventor(s): Rickey; Michael E. & Ramstack; J. Michael & Lewis; Danny H.
Assignee(s): Alkermes Controlled Therapeutics Inc.
A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymer, an active agent, and a solvent. An immiscible second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The two phases are immersed in a quench liquid that includes a quench medium and a quantity of the solvent. The quantity of the solvent is selected to control a rate of extraction of the solvent from the first phase. The first phase is isolated in the form of microparticles. Also disclosed is a microencapsulated active agent prepared by the method for preparing biodegradable, biocompatible microparticles.Patent expiration dates:
- May 2, 2017✓
- November 2, 2017✓
- May 2, 2017
Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Patent 6,110,921
Issued: August 29, 2000
Inventor(s): Mesens; Jean & Rickey; Michael E. & Atkins; Thomas J.
Assignee(s): Alkermes Controlled Therapeutics Inc. II
Janssen Pharmaceutica
The invention relates to a method of treating psychotic disorders comprising a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof.Patent expiration dates:
- November 19, 2013✓
- May 19, 2014✓
- November 19, 2013
Preparation of microparticles having a selected release profile
Patent 6,194,006
Issued: February 27, 2001
Inventor(s): Lyons; Shawn L. & Ramstack; J. Michael & Wright; Steven G.
Assignee(s): Alkermes Controlled Therapeutics Inc. II
An improved method for preparing microparticles that exhibit controlled release of an effective amount of an active agent over an extended period of time. More particularly, a method is provided for preparing microparticles having a selected release profile for release of active agent contained in the microparticles. By adjusting the degree of drying that is performed during the preparation of the microparticles, the release profile can be controlled. By performing no intermediate drying, an initial burst and a substantially linear release profile is achieved. By performing substantially complete intermediate drying, an initial lag phase and a substantially sigmoidal release profile is achieved.Patent expiration dates:
- December 30, 2018✓
- June 30, 2019✓
- December 30, 2018
Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Patent 6,368,632
Issued: April 9, 2002
Inventor(s): Jean; Mesens & Michael E.; Rickey & Thomas J.; Atkins
Assignee(s): Janssen Pharmaceutica
Alkermes Controlled Therapeutics Inc. II
Method of treating warm blooded animals suffering from psychotic disorders. The method includes administering a pharmaceutically effective amount of sustained-release microparticles that include risperidone, or a pharmaceutically acceptable acid addition salt thereof, and a biodegradable and biocompatible polymeric matrix.Patent expiration dates:
- November 19, 2013✓
- May 19, 2014✓
- November 19, 2013
Preparation of microparticles having a selected release profile
Patent 6,379,703
Issued: April 30, 2002
Inventor(s): Shawn L.; Lyons & J. Michael; Ramstack & Steven G.; Wright
Assignee(s): Alkermes Controlled Therapeutics Inc., II
An improved method for preparing microparticles that exhibit controlled release of an effective amount of an active agent over an extended period of time. More particularly, a method is provided for preparing microparticles having a selected release profile for release of active agent contained in the microparticles. By adjusting the degree of drying that is performed during the preparation of the microparticles, the release profile can be controlled. By performing no intermediate drying, an initial burst and a substantially linear release profile is achieved. By performing substantially complete intermediate drying, an initial lag phase and a substantially sigmoidal release profile is achieved.Patent expiration dates:
- December 30, 2018✓
- June 30, 2019✓
- December 30, 2018
Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
Patent 6,403,114
Issued: June 11, 2002
Inventor(s): Michael E.; Rickey & J. Michael; Ramstack & Danny H.; Lewis
Assignee(s): Alkermes Controlled Therapeutics Inc. II
A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymer, an active agent, and a solvent. A second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The discontinuous first phase is separated from the continuous second phase. The residual level of solvent in the discontinuous first phase is reduced to less than about 2% by weight.Patent expiration dates:
- May 2, 2017✓
- November 2, 2017✓
- May 2, 2017
Preparation of microparticles having a selected release profile
Patent 6,596,316
Issued: July 22, 2003
Inventor(s): Shawn L.; Lyons & J. Michael; Ramstack & Steven G.; Wright
Assignee(s): Alkermes Controlled Therapeutics, Inc. II
An improved method for preparing microparticles that exhibit controlled release of an effective amount of an active agent over an extended period of time. More particularly, a method is provided for preparing microparticles having a selected release profile for release of active agent contained in the microparticles. By adjusting the degree of drying that is performed during the preparation of the microparticles, the release profile can be controlled. By performing no intermediate drying, an initial burst and a substantially linear release profile is achieved. By performing substantially complete intermediate drying, an initial lag phase and a substantially sigmoidal release profile is achieved.Patent expiration dates:
- December 30, 2018✓
- June 30, 2019✓
- December 30, 2018
Preparation of injectable suspensions having improved injectability
Patent 6,667,061
Issued: December 23, 2003
Inventor(s): J. Michael; Ramstack & M. Gary I.; Riley & Stephen E.; Zale & Joyce M.; Hotz & Olufunmi L.; Johnson
Assignee(s): Alkermes Controlled Therapeutics, Inc.
Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.Patent expiration dates:
- May 25, 2020✓
- November 25, 2020✓
- May 25, 2020
Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Patent 7,547,452
Issued: June 16, 2009
Inventor(s): Atkins; Thomas J. & Rickey; Michael E. & Mesens; Jean
Assignee(s): Alkermes, Inc.
Janssen Pharmaceutica, N.V
Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.Patent expiration dates:
- November 19, 2013✓
- May 19, 2014✓
- November 19, 2013
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- May 15, 2012 - USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- May 15, 2012 - MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
See also...
- Risperdal Consta Consumer Information (Drugs.com)
- Risperdal Consta Consumer Information (Wolters Kluwer)
- Risperdal Consta Advanced Consumer Information (Micromedex)
- Risperidone Consumer Information (Drugs.com)
- Risperidone Consumer Information (Wolters Kluwer)
- Risperidone Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
- Risperidone Solution Consumer Information (Wolters Kluwer)
- Risperidone Tablets Consumer Information (Wolters Kluwer)
- Risperidone Consumer Information (Cerner Multum)
- Risperidone Advanced Consumer Information (Micromedex)
- Risperidone Intramuscular Advanced Consumer Information (Micromedex)
- Risperidone AHFS DI Monographs (ASHP)
No comments:
Post a Comment